User profiles for Philip Crosbie

Phil Crosbie

University of Manchester
Verified email at manchester.ac.uk
Cited by 9598

The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets

SL Wood, M Pernemalm, PA Crosbie… - Cancer treatment …, 2014 - Elsevier
Non-small cell lung cancer (NSCLC) accounts for >80% of lung cancer cases and currently
has an overall five-year survival rate of only 15%. Patients presenting with advanced stage …

[HTML][HTML] Tracking the evolution of non–small-cell lung cancer

…, L Joseph, AM Quinn, PA Crosbie… - … England Journal of …, 2017 - Mass Medical Soc
Background Among patients with non–small-cell lung cancer (NSCLC), data on intratumor
heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. …

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

…, R Shah, L Joseph, A Marie Quinn, PA Crosbie… - Nature, 2017 - nature.com
The early detection of relapse following primary surgery for non-small-cell lung cancer and
the characterization of emerging subclones, which seed metastatic sites, might offer new …

[HTML][HTML] Tracking genomic cancer evolution for precision medicine: the lung TRACERx study

…, A Capitano, M Chetty, M Cobbold, P Crosbie… - PLoS …, 2014 - journals.plos.org
The importance of intratumour genetic and functional heterogeneity is increasingly recognised
as a driver of cancer progression and survival outcome. Understanding how tumour …

Implementing lung cancer screening: baseline results from a community-based 'Lung Health Check'pilot in deprived areas of Manchester

PA Crosbie, H Balata, M Evison, M Atack… - Thorax, 2019 - thorax.bmj.com
We report baseline results of a community-based, targeted, low-dose CT (LDCT) lung cancer
screening pilot in deprived areas of Manchester. Ever smokers, aged 55–74 years, were …

[PDF][PDF] Allele-specific HLA loss and immune escape in lung cancer evolution

…, E Fontaine, R Booton, M Evison, P Crosbie… - Cell, 2017 - cell.com
Immune evasion is a hallmark of cancer. Losing the ability to present neoantigens through
human leukocyte antigen (HLA) loss may facilitate immune evasion. However, the …

Progress and prospects of early detection in lung cancer

S Blandin Knight, PA Crosbie, H Balata… - Open …, 2017 - royalsocietypublishing.org
Lung cancer is the leading cause of cancer-related death in the world. It is broadly divided
into small cell (SCLC, approx. 15% cases) and non-small cell lung cancer (NSCLC, approx. 85…

Molecular histology of lung cancer: from targets to treatments

SL Wood, M Pernemalm, PA Crosbie… - Cancer treatment …, 2015 - Elsevier
Lung cancer is the leading cause of cancer-related death worldwide with a 5-year survival
rate of less than 15%, despite significant advances in both diagnostic and therapeutic …

[PDF][PDF] Fc effector function contributes to the activity of human anti-CTLA-4 antibodies

…, E Fontaine, R Booton, M Evison, P Crosbie… - Cancer cell, 2018 - cell.com
With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we
demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate …

Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse

…, C Hiley, S Veeriah, Y Summers, P Crosbie… - Nature medicine, 2019 - nature.com
Approximately 50% of patients with early-stage non-small-cell lung cancer (NSCLC) who
undergo surgery with curative intent will relapse within 5 years 1 , 2 . Detection of circulating …